Overview
Exact
Exact Science is a leading, global, advanced cancer diagnostics company. It develops non-invasive tests for the early detection of colorectal cancer and precancerous lesions. Its flagship screening product, the Cologuard test, is a patient-friendly, non-invasive, stool-based DNA (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its Oncotype test is
...
Read More consist of its flagship line of Oncotype DX gene expression tests for breast, prostate and colon cancers. Almost all of its revenue comes from the US.
Read Less
Read More consist of its flagship line of Oncotype DX gene expression tests for breast, prostate and colon cancers. Almost all of its revenue comes from the US.
Read Less
#
998
Fortune 1000 Revenue Rank
Kevin T Conroy
See more contacts
Medical and Diagnostic Laboratories
,
Pharmaceutical and Medicine Manufacturing
,
Ambulatory Health Care Services
,
Health Care and Social Assistance
,
Medical laboratories
See All Industries Pharmaceutical preparations
See Fewer Industries
See All Industries Pharmaceutical preparations
See Fewer Industries
Child Care Services
,
Community Food and Housing, and Emergency and Other Relief Services
,
Continuing Care Retirement Communities and Assisted Living Facilities for the Elderly
,
General Medical and Surgical Hospitals
,
Home Health Care Services
,
Individual and Family Services
,
Nursing Care Facilities (Skilled Nursing Facilities)
,
Offices of Dentists
View more , Offices of Other Health Practitioners , Offices of Physicians , Other Ambulatory Health Care Services , Other Residential Care Facilities , Outpatient Care Centers , Psychiatric and Substance Abuse Hospitals , Residential Intellectual and Developmental Disability, Mental Health, and Substance Abuse Facilities , Specialty (except Psychiatric and Substance Abuse) Hospitals Vocational Rehabilitation Services
View fewer
View more , Offices of Other Health Practitioners , Offices of Physicians , Other Ambulatory Health Care Services , Other Residential Care Facilities , Outpatient Care Centers , Psychiatric and Substance Abuse Hospitals , Residential Intellectual and Developmental Disability, Mental Health, and Substance Abuse Facilities , Specialty (except Psychiatric and Substance Abuse) Hospitals Vocational Rehabilitation Services
View fewer
?
?
?
Modelled
?
Actual
$2.76 billion
Actual
10.37%
$5,928
DEC
?
?
NASDAQ:EXAS
Contacts
Get in Touch with 5 Principals* and 2,788 Contacts
-
Kevin T ConroyChairman of the Board and President and Chief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$2.76 billion
USD
Actual
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $211 | $156 | -$224 |
| Net Investing Cash | -$442 | $50 | $74 |
| Net Financing Cash | $232 | $160 | $76 |
| Net Change in Cash | $0 | $366 | -$73 |
| Cash at Beginning of Period | $610 | $243 | $316 |
| Cash at End of Period | $607 | $610 | $243 |
| Capital Expenditure | -$136 | -$124 | -$214 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $601 | $605 | $242 |
| Accounts Receivable | $249 | $204 | $158 |
| Inventories | $162 | $127 | $118 |
| Other Current Assets | $559 | $258 | $463 |
| Asset Summary | |||
| Total Current Assets | $1,571 | $1,194 | $982 |
| Tangible Fixed Assets | $811 | $842 | $852 |
| Intangible Assets | $1,010 | $1,890 | $1,956 |
| Total Assets | $5,928 | $6,471 | $6,227 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $90 | $79 | $75 |
| Short-Term Debt | $249 | $50 | $ |
| Other Current Liabilities | $393 | $386 | $338 |
| Liability Summary | |||
| Total Current Liabilities | $732 | $515 | $413 |
| Long-Term Debt | $2,321 | $2,314 | $2,236 |
| Other Long-Term Liabilities | $316 | $336 | $352 |
| Total Liabilities | $3,526 | $3,326 | $3,184 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $2 | $2 | $2 |
| Retained Earnings | -$4,498 | -$3,469 | -$3,265 |
| Equity Summary | |||
| Total Equity | $2,402 | $3,145 | $3,043 |
| Shares Outstanding | 185,616,438 | 181,364,180 | 177,925,631 |